Spark Plug Pipe

via NEWMEDIAWIRE — Apotheca Biosciences (OTC PINK: PCFP), a developer of cutting-edge medical products, nutraceuticals, drug formulations and cannabis delivery technologies for the healthcare and consumer care industry, announces today that the Company and CB Scientific (CBSC) have joined forces to develop and unveil next generation Cannabis based THC & Hemp based infused energy and chill drinks for the consumers and patients under the brand “Magic Dragon High” and “DAVA”. DAVA Brands will initially produce Hemp based CBD infused beverages for the patients using targeted proprietary formulations. Hemp based CBD infused energy & chill drinks will be sold globally through all channels, which may include eBay and Amazon under the brand “Magic Dragon High”.

Apotheca have been working and developing exciting Hemp and CBD based formulations since 2015 using leading edge technologies and great talents. We believe we are on the cusp of a great change coming to the world with the advent of Hemp and Cannabis as medicinal harbingers, hence making companies such as PCFP pioneers in a vast undeveloped market. The current reclassification of CBD by the DEA has drastically reduced the previous headwinds.

The Company will be marketing and selling both products developed under the brands DAVA for patients and Magic Dragon High for general public. The Company has set a goal of producing over 500,000 (or more) bottles of Hemp CBD infused beverages for this calendar year.

Growing Global Market

The highest estimates have global legal cannabis sales reaching nearly $146 billion by 2025. With recreational pot in Canada, the legal recreational sales bonanza is beginning. In a matter of days, Canada will legalize recreational marijuana–and it will be the staging ground for other parts of the world.

Wells Fargo analysts estimates that cannabis-infused drinks are going to be a massive market. They’re eyeing $50 billion in sales annually in the U.S. That would give cannabis-infused drinks nearly half of the entire U.S. beer market sales annually.

According to new market data from Packaged Facts, the energy drinks sector comprises an increasing portion of the non-alcoholic beverage market, and as a sector, has grown 60% from 2008-2012 with a total U.S. sale of more than $12.5 billion in 2012. According to “Energy Drinks & Shots Market Trends in the U.S.”, sales of energy drinks grew to a value of $21.5 billion by 2017, driven by expansion in retail distribution, and strong potential in new product development.

Apotheca Biosciences is developing revolutionary formulas and medical delivery systems to transform treatment methods from pain relief to Alzheimer. With the growing understanding of the effectiveness of CBD, it is impossible not to be a part of the growing CBD industry and Apotheca Biosciences will be at the forefront.

<b>

About Apotheca Biosciences Inc.</b>

Apotheca is a developer of cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry. Its pipeline of products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids. Apotheca believes that it can deliver meaningful benefits using its technologies to the world’s aging population.

To request further information about Apotheca, please email info@apothecabio.com, or visit its website at http://www.apothecabiosciences.com/, or visit it on FB @apotheca and Twitter @apotheca

<b>Forward-Looking Statements</b>

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact:Media Contact: (727) 228-3994Apotheca Bioscienceshttp://www.apothecabiosciences.cominfo@apothecabio.comTwitter - @apothecaFacebook - apothecaTelegram- apotheca

<img src=”http://www.globenewswire.com/newsroom/ti?ndecode=MTUwIzczOTkwMjg=” alt=”” width=”1″ height=”1″/>

Stock Symbols